A Phase 2 interventional study of NOE-105 and Placebo in Childhood-Onset Fluency Disorder, sponsored by Noema Pharma AG. Completed at 9 sites in 2 countries. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by Noema Pharma AG · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to evaluate the effectiveness of NOE-105 on speech fluency without the known antipsychotic-induced side effects of commonly used treatments for childhood onset fluency disorder (COFD).
NOE-105 is an investigational selective PDE10A inhibitor with a potential therapeutic effect for the treatment of COFD. In this study adult male patients may be randomized to a double-blind, placebo-controlled, parallel group treatment with NOE-105 or placebo once daily. The study is designed to find the maximum tolerated dose of NOE-105 and thereafter, to maintain the participants at this dose until they have completed a total of 10 weeks treatment period. Following up to 10 weeks of treatment, participants will visit the study site for a follow-up visit within 28 (± 7) days of the date of the last dose of study treatment.
Noema Pharma AG is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Male patients must use a condom during the treatment period and until the end of relevant systemic exposure in the male participant, plus a further 90-day period. In addition, for a non-pregnant partner.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating doses of NOE-105 capsules
Drug: NOE-105
Escalating doses of matching placebo
Drug: Placebo
Escalating dose levels of NOE-105 will be given and maximum tolerated dose will be maintained
Also known as: Escalating dose levels of NOE-105
Escalating dose levels of matching Placebo will be given
Also known as: Placebo to match
Change From Baseline to End of 6 Weeks in Total MLGSSS
MLGSSS refers to Maguire-Leal-Garibaldi Self-rated Stuttering Scale. The scale includes ten questions that are assessed on a 0 to 10 scale with 0 being no impact and 10 being highest impact. The total score ranges from 0 to 100 with the higher the score the worse the stuttering.
Time frame: 43 days
Change From Baseline in Sheehan Disability Scale
The Sheehan Disability Scale (SDS) is a brief, self-report tool that assesses disability or functional impairment in the domains of (1) Work/School life, (2) Social life, and (3) Family life/home responsibilities. Each is assessed on a 10 point scale with 0 being no impact, and 10 being highest impact. Each item is rated from 0 (not at all) to 10 (extremely) impairment. Each domain score is added to provide a total score from 0-30 total score with 0 (no impairment) and 30 is severe impairment. The change from the Baseline assessment have been provided.
Time frame: Up to 71 days
Change From Baseline to End Point in Clinician-rated Stuttering Severity Instrument-4
SSI-4 is a validated scale to evaluate speech fluency including frequency, duration, physical concomitants and the naturalness of the speech. The score ranges from 10 (mildest) to 46 (most severe). The results show the change from Baseline in the SSI-4
Time frame: Up to 71 days
| Milestone | Active | Placebo |
|---|---|---|
| Started | 34 | 31 |
| Full analysis set | 33 | 29 |
| Completed | 19 | 26 |
| Not completed | 15 | 5 |
MLGSSS refers to Maguire-Leal-Garibaldi Self-rated Stuttering Scale. The scale includes ten questions that are assessed on a 0 to 10 scale with 0 being no impact and 10 being highest impact. The total score ranges from 0 to 100 with the higher the score the worse the stuttering.
| Score on a scale | Active | Placebo |
|---|---|---|
| Change From Baseline to End of 6 Weeks in Total MLGSSS | -7.0 ± 13.32 | -5.5 ± 6.72 |
The Sheehan Disability Scale (SDS) is a brief, self-report tool that assesses disability or functional impairment in the domains of (1) Work/School life, (2) Social life, and (3) Family life/home responsibilities. Each is assessed on a 10 point scale with 0 being no impact, and 10 being highest impact. Each item is rated from 0 (not at all) to 10 (extremely) impairment. Each domain score is added to provide a total score from 0-30 total score with 0 (no impairment) and 30 is severe impairment. The change from the Baseline assessment have been provided.
| score on a scale | Active | Placebo |
|---|---|---|
| Change From Baseline in Sheehan Disability Scale | -0.6 ± 8.23 | -1.3 ± 5.82 |
SSI-4 is a validated scale to evaluate speech fluency including frequency, duration, physical concomitants and the naturalness of the speech. The score ranges from 10 (mildest) to 46 (most severe). The results show the change from Baseline in the SSI-4
| units on a scale | Active | Placebo |
|---|---|---|
| Change From Baseline to End Point in Clinician-rated Stuttering Severity Instrument-4 | -3.0 ± 6.5 | -2.7 ± 4.78 |
MLGSSS refers to Maguire-Leal-Garibaldi Self-rated Stuttering Scale. The scale includes ten questions that are assessed on a 0 to 10 scale with 0 being no impact and 10 being highest impact. The total score ranges from 0 to 100 with the higher the score the worse the stuttering. Analysis of a subset of participant with a Baseline MLGSSS of \> 24, in other words this analysis excludes those with mild stuttering as measured by MLGSSS. See the description for the first outcome measure for a description of the scale. The results show the change from baseline.
| score on a scale | Active | Placebo |
|---|---|---|
| Change in MLGSSS From Baseline in More Severe Population | -14.8 ± 12.54 | -9.1 ± 8.81 |
Collected over Adverse events were collected for the duration of the trial (71 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active | 0/34 (0%) | 0/34 (0%) | 23/34 (67.6%) |
| Placebo | 0/31 (0%) | 0/31 (0%) | 13/31 (41.9%) |
| Event | Active | Placebo |
|---|---|---|
| SedationNervous system disorders | 8/34 | 1/31 |
| NasopharyngitisInfections and infestations | 0/34 | 4/31 |
| DystoniaNervous system disorders | 3/34 | 0/31 |
| SomnolenceNervous system disorders | 3/34 | 0/31 |
| AkathisiaNervous system disorders | 3/34 | 0/31 |
| RestlessnessPsychiatric disorders | 3/34 | 0/31 |
| Upper respiratory tract infectionInfections and infestations | 1/34 | 2/31 |
| Muscle twitchingMusculoskeletal and connective tissue disorders | 0/34 | 2/31 |
| TremorNervous system disorders | 2/34 | 1/31 |
| BradykinesiaNervous system disorders | 2/34 | 0/31 |
| Age, Continuous(years) | Active | Placebo | Total |
|---|---|---|---|
| Mean | 31.1 ± 10.09 | 34.3 ± 10.25 | 32.6 ± 10.22 |
| Sex: Female, Male(Participants) | Active | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 34 | 31 | 65 |
| Race (NIH/OMB)(Participants) | Active | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 10 | 9 | 19 |
| White | 17 | 15 | 32 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 5 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Active | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 6 |
| Not Hispanic or Latino | 31 | 27 | 58 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Maguire-Leal-Garibaldi Self-rated Stuttering Scale(score on a scale) | Active | Placebo | Total |
|---|---|---|---|
| Mean | 32.1 ± 14.23 | 33.3 ± 11.16 | 32.7 ± 12.86 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Oct 2023, 14 months.
Results were first posted in Feb 2026, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Childhood-Onset Fluency Disorder
Noema Pharma AG